NASDAQ:CVKD Cadrenal Therapeutics (CVKD) Stock Price, News & Analysis $1.54 -0.03 (-1.60%) As of 04:00 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsInsider TradesNews and TrendsOwnershipSEC Filings About Cadrenal Therapeutics Stock (NASDAQ:CVKD) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Cadrenal Therapeutics alerts:Sign Up Key Stats Today's Range$1.50▼$1.6050-Day Range$1.53▼$3.6052-Week Range$1.49▼$14.64Volume30,133 shsAverage Volume40,072 shsMarket Capitalization$5.50 millionP/E RatioN/ADividend YieldN/APrice Target$13.00Consensus RatingHold Company Overview Cadrenal Therapeutics, Inc. operates as a clinical development biopharmaceutical company. The company focuses on developing Tecarfarin, a novel oral and reversible anticoagulant to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions requiring chronic anticoagulation, such as patients with left ventricular assist devices, end-stage kidney disease, atrial fibrillation, and thrombotic anti-phospholipid syndrome. Cadrenal Therapeutics, Inc. was incorporated in 2022 and is headquartered in Ponte Vedra, Florida. Read More Cadrenal Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks49th Percentile Overall ScoreCVKD MarketRank™: Cadrenal Therapeutics scored higher than 49% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.2 / 5Analyst RatingHold Consensus RatingCadrenal Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no strong buy ratings, 1 buy rating, no hold ratings, and 1 sell rating.Upside PotentialCadrenal Therapeutics has a consensus price target of $13.00, representing about 744.2% upside from its current price of $1.54.Amount of Analyst CoverageCadrenal Therapeutics has only been the subject of 1 research reports in the past 90 days.Read more about Cadrenal Therapeutics' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Cadrenal Therapeutics are expected to grow in the coming year, from ($4.22) to ($3.25) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Cadrenal Therapeutics is -0.31, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Cadrenal Therapeutics is -0.31, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioCadrenal Therapeutics has a P/B Ratio of 1.34. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Cadrenal Therapeutics' valuation and earnings. Short Interest3.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted2.14% of the float of Cadrenal Therapeutics has been sold short.Short Interest Ratio / Days to CoverCadrenal Therapeutics has a short interest ratio ("days to cover") of 1.8, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Cadrenal Therapeutics has recently increased by 6.51%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldCadrenal Therapeutics does not currently pay a dividend.Dividend GrowthCadrenal Therapeutics does not have a long track record of dividend growth. News and Social Media2.8 / 5News SentimentN/A News SentimentCadrenal Therapeutics has a news sentiment score of 1.43. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.92 average news sentiment score of Healthcare companies.News Coverage This WeekMarketBeat has tracked 1 news article for Cadrenal Therapeutics this week, compared to 4 articles on an average week.Search InterestOnly 3 people have searched for CVKD on MarketBeat in the last 30 days. This is a decrease of -70% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added Cadrenal Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Company Ownership1.3 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Cadrenal Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $326,946.00 in company stock.Percentage Held by Insiders14.59% of the stock of Cadrenal Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions7.92% of the stock of Cadrenal Therapeutics is held by institutions.Read more about Cadrenal Therapeutics' insider trading history. Receive CVKD Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Cadrenal Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. CVKD Stock News HeadlinesQ3 Earnings Estimate for CVKD Issued By Noble FinancialAugust 21, 2026 | americanbankingnews.comQ3 EPS Forecast for Cadrenal Therapeutics Lowered by AnalystAugust 20, 2026 | americanbankingnews.com#1 Stock to Own as Trump Launches Historic Mission Backing "Medical AI"The federal government is throwing its full support behind a new class of AI technology, in what's being called the biggest push since the Apollo moon landing. This AI reportedly works 10,000 times faster than human PhDs and could eventually be worth 500 times more than ChatGPT. Elon Musk has called the underlying tech the most disruptive force in history.August 28 at 1:00 AM | Stansberry Research (Ad)What is Noble Financial's Forecast for CVKD Q1 Earnings?August 20, 2026 | americanbankingnews.comCadrenal Therapeutics Reports Second Quarter 2026 Financial Results; Provides a Corporate Update on the Cardiac Acute Critical Care Franchise and the Strategic Partnering ProcessAugust 13, 2026 | globenewswire.comSignal Proxy Intelligence Recommends Full Support for All Five Items at CADRENAL THERAPEUTICS, INC. Annual Meeting (NASDAQ:CVKD)August 5, 2026 | usatoday.comCadrenal Therapeutics Solidifies Multi-Indication Strategy for CAD-1005 in Cardiac Acute Critical Care Following Competitor’s Phase 3 DiscontinuationAugust 3, 2026 | markets.businessinsider.comCVKD: Positive CAD-1005 data accelerates transition toward business development strategyAugust 3, 2026 | msn.comSee More Headlines CVKD Stock Analysis - Frequently Asked Questions How have CVKD shares performed this year? Cadrenal Therapeutics' stock was trading at $6.78 at the start of the year. Since then, CVKD shares have decreased by 77.3% and is now trading at $1.54. How were Cadrenal Therapeutics' earnings last quarter? Cadrenal Therapeutics, Inc. (NASDAQ:CVKD) posted its quarterly earnings data on Thursday, August, 13th. The company reported ($1.14) earnings per share for the quarter, topping analysts' consensus estimates of ($1.42) by $0.28. When did Cadrenal Therapeutics IPO? Cadrenal Therapeutics (CVKD) raised $7 million in an IPO on Friday, January 20th 2023. The company issued 1,400,000 shares at a price of $5.00 per share. How do I buy shares of Cadrenal Therapeutics? Shares of CVKD stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Cadrenal Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Cadrenal Therapeutics investors own include Clean Energy Fuels (CLNE), Paycom Software (PAYC), uniQure (QURE), AbCellera Biologics (ABCL), Mitsubishi UFJ Financial Group (MUFG) and Oatly Group (OTLY). Company Calendar Last Earnings8/13/2026Today8/28/2026Next Earnings (Estimated)11/09/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Red Zone (6m+) 1-Year History Aug 25 Nov 25 Feb 26 May 26 Aug 26 CVKD's financial health is in the Red zone, according to TradeSmith. CVKD has been in this zone for over 6 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolNASDAQ:CVKD CIK1937993 Webwww.cadrenal.com Phone904-300-0701FaxN/AEmployees4Year Founded2022Price Target and Rating Average Price Target for Cadrenal Therapeutics$13.00 High Price Target$13.00 Low Price Target$13.00 Potential Upside/Downside+744.2%Consensus RatingHold Rating Score (0-4)2.00 Research Coverage2 Analysts Profitability EPS (Trailing Twelve Months)($4.90) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$13.24 million Net MarginsN/A Pretax MarginN/A Return on Equity-406.41% Return on Assets-273.80% Debt Debt-to-Equity RatioN/A Current Ratio3.73 Quick Ratio3.73 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$1.15 per share Price / Book1.34Miscellaneous Outstanding Shares3,570,000Free Float3,047,000Market Cap$5.50 million OptionableNot Optionable Beta1.84 Social Links (Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Click the link to see our list of which EV stocks show the most long-term potential.Get This Free Report This page (NASDAQ:CVKD) was last updated on 8/28/2026 by MarketBeat.com Staff. From Our PartnersWall Street is staring at the wrong AI tradeAnthropic just signed a 9.1 billion dollar, 20 year data center agreement covering 191 megawatts of capacity, ...The Oxford Club | SponsoredElon Musk’s Hushed FCC Filing. Sept 25th.Elon Musk quietly filed a document with the federal government tied to artificial intelligence, one of the lar...Paradigm Press | SponsoredThe retirement stock I'd buy before Nvidia todayIn 2014, Marc Chaikin pointed readers toward Nvidia. Now the 60-year Wall Street veteran and creator of the Ch...Chaikin Analytics | SponsoredSmall Colorado Company (Backed by Sam Altman) Could Save U.S. Power GridA small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...Altimetry | SponsoredBuy These Stocks Before August 31stKeith Kaplan has invested $17 million into his own AI research platform, now used by 180,000 investors worldwi...TradeSmith | SponsoredBank of America grew this stake 139%Bank of America raised its stake in a small gold company by 139%. Jane Street increased its position by 159%, ...Behind the Markets | SponsoredI found Rolls-Royce at $2 - now I see the same setup againIn 2022, Karim Rahemtulla recommended Rolls-Royce under $2 - a misunderstood aerospace name the market had wri...Monument Traders Alliance | SponsoredHow a schoolteacher turned $100 into $355,000In 1903, a Detroit schoolteacher put $100 into a struggling carmaker named Ford, just as cheap gasoline met th...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Cadrenal Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Cadrenal Therapeutics With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
